Avadel Pharmaceuticals is a specialty biopharmaceutical company that develops therapies for central nervous system and rare disease indications. The company’s primary focus lies in creating novel oral delivery systems to enhance drug performance and patient adherence. Its lead candidate, FT218, is a once-nightly formulation of sodium oxybate designed to treat idiopathic hypersomnia and other sleep disorders, and is undergoing regulatory review in the United States.
Beyond its sleep-focused portfolio, Avadel is advancing additional pipeline programs in areas such as acute and chronic pain management, oncology supportive care, and rare pediatric diseases. These efforts leverage the company’s proprietary multi-layered formulation platform, which aims to optimize release profiles and improve safety and tolerability. Avadel collaborates with academic institutions and contract development organizations to drive its products through preclinical development and clinical trials.
Headquartered in Dublin, Ireland, Avadel maintains corporate offices and research facilities in the United States and Europe. The company was established in 2017 following a strategic spin-out from Flamel Technologies and has since built a global infrastructure that includes manufacturing sites in Ireland and the U.S., along with partnerships for commercialization in key markets across North America and Europe.
Under the leadership of CEO Gregory Divis, Avadel’s executive team combines extensive experience in pharmaceutical research, regulatory affairs, and commercial strategy. The company is committed to patient-centric innovation, aiming to bring safer, more effective treatments to underserved populations while navigating complex regulatory pathways worldwide.
AI Generated. May Contain Errors.
